BTG Management Services Limited

BTG Management Services Limited, a biopharmaceutical company, focuses on the development, manufacture, and marketing of specialized hospital products for critical care and cancer primarily in the United Kingdom, the United States, and Australia. The company offers various products for application in medical emergencies, such as overdose, poisoning, and life-threatening infections. It offers critical care products, which include CroFab, a polyclonal antibody fragment that neutralizes venom from North American Crotalid snakes; DigiFab, a polyclonal antibody fragment for the treatment of life-threatening digoxin toxicity or overdose; CytoFab, which is used in the treatment of severe sepsis; and ViperaTAb, a venom antidote product for the treatment of snakebites; and Digoxin Immune Fabs, which are polyclonal antibody fragments used in the treatment of pre-eclampsia, a complication of pregnancy. The company also provides cancer products, including Voraxaze, an intervention treatment when methotrexate blood levels are elevated following high dose therapy for the treatment of cancer; OncoGel for oesophageal and primary brain cancers; Prolarix for primary liver cancer and other selected tumours; and Acadra/acadesine, a nucleoside analogue for the treatment of chronic lymphocytic leukaemia and other B-cell malignancies. In addition, it offers CoVaccine HT, a proprietary adjuvant used in prophylactic and therapeutic vaccines; BSE diagnostic test, which is used for the detection of bovine spongiform encephalopathy; and Angiotensin, a therapeutic vaccine for the treatment of high blood pressure/hyper tension. The company is based in Runcorn, the United Kingdom. BTG Management Services Limited operates as a subsidiary of Btg International (Holdings) Limited.